Galectin-3对甲状腺乳头状癌早期病变的诊断意义

 目的 比较Galectin-3（Gal-3）在甲状腺乳头状癌及其早期病变和甲状腺良性病变中的表达差异，明确其临床意义。方法 采用免疫组化EnVision二步法检测329例甲状腺手术标本中Gal-3蛋白的表达情况。结果 Gal-3蛋白在甲状腺乳头状微癌及甲状腺乳头状非典型增生中的表达阳性率分别为83．3％、77．8％，显著高于结节性甲状腺肿（30．9％）、腺瘤（43．7％）及甲状腺炎（16．1％）。结论 甲状腺Gal-3表达在甲状腺乳头状微癌及非典型增生组织中显著高于甲状腺良性病变，Gal-3检测使甲状腺乳头状癌早期病变易于发现。

Diagnostic Significance of Galectin-3 in Early Phase of Thyroid Papillary Carcinoma

Objective To investigate the difference of Galectin-3 expression in papillary thyroid carcinoma especially the early phase and benign thyroid diseases, then determine the clinical significance of Galectin-3. Methods The hundred and twenty-nine samples of resected thyroid nodules were examined by En vision immunohistochemical technique to detect the expression of Galectin-3. Results The expression rate of Galectin-3 was 83. 3% in thyroid papillary micro-carcinoma and 77. 8% in atypical hyperplasia, 30. 9% in nodular goiter,43.7% in adenoma and 16. 1% in thyroiditis. The positive expression rate of Galectin-3 in the early phase of papillary thyroid carcinoma was higher than in benign thyroid diseases. Condusion The difference of Galectin-3 expression between the early phase of papillary thyroid carcinoma and benign thyroid diseases were statistically significant. The detection of Galection-3 may conduce to the diagnose of papillary thyroid carcinoma in the early phase.